Logged in as
Pinch to Zoom Endocrine Meds
Identify the blue label
Last 24 Days
1234
5678
9101112
13141516
17181920
21222324
April 30
061218
171319
281420
391521
4101622
5111723
Yesterday
061218
171319
281420
391521
4101622
5111723
Today
061218
171319
281420
391521
4101622
5111723
Alendronate, Risedronate, Desiccated thyroid, Levothyroxine, Rosiglitazone
Generic
Rosiglitazone
12345
12345
Generic
Risedronate
12345
12345
Generic
Desiccated thyroid
12345
12345
Generic
Alendronate
12345
12345
Generic
Levothyroxine
12345
12345
Category
Brandname
 
 

Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.

Desiccated thyroid, also known as thyroid extract, is thyroid gland that has been dried and powdered for medical use. It is used to treat hypothyroidism. It is less preferred than levothyroxine. It is taken by mouth. Maximal effects may take up to 3 weeks to occur.

Levothyroxine, also known as L-thyroxine, is a manufactured form of the thyroid hormone thyroxine (T4). It is used to treat thyroid hormone deficiency, including the severe form known as myxedema coma. It may also be used to treat and prevent certain types of thyroid tumors. It is not indicated for weight loss. Levothyroxine is taken by mouth or given by injection into a vein. Maximum effect from a specific dose can take up to six weeks to occur.

Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.

Rosiglitazone is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.